Accro Bioscience | RoundOS

Weekly digest by email

Loading companies…

Accro Bioscience | RoundOS

Weekly digest by email

Funding history

1 round · 1 with disclosed amounts

Announced	Round	Amount	Investors
May 18, 2026	Series C	$50M	Cenova Capital — Role not disclosedLAV — Role not disclosedOrbiMed — Role not disclosedOriza Holdings — Role not disclosedShenzhen Capital Group — Role not disclosedTCG Crossover — Role not disclosed

Investors

Cenova CapitalSeries C LAVSeries C OrbiMedSeries C Oriza HoldingsSeries C Shenzhen Capital GroupSeries C TCG CrossoverSeries C

Coverage

May 18, 2026Accro Bioscience · Series C

Similar companies

AusperBioDevelops oligonucleotide therapeutics targeting chronic hepatitis B$120M · Series C

MetriportOpen-source healthcare data infrastructure unifying patient records for clinicians$26M · Series A

ProFound TherapeuticsUses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia$35M · Strategic

Sources

accropeutics.com ↗